Tuesday, August 24, 2021 1:58:18 PM
--There will be a full clinical trial in Brazil , someone posted here recently it was approved .. so I will expect it should be very soon..And hopefully it will start and finish very fast , showing to the world what drug leronlimab is..
--People dying around the world , and not one good drug approved for immune stage of covid ..
How I understand that going recently with a family member threw this terrible situation.
We need leronlimab approval asap.
--Leronlimab is also -- HIV drug ,
When refusal to file was issue , it was not because of not clinically statistical results, it was because of collateral things , not finished ROT , wrong papers file etc.
Clinical efficacy with leronlimab was as no other drug approved,
81% efficacy with 350 mg of leronlimab , compare to 45% efficacy with Maraviroc , and 43% with ibalizumab , in the same category of patients..
And so many more other benefits HIV patients should have when using leronlimab , of course studies ongoing in some , or will be initiated in others , to prove all this , but look that leronlimab will also control.
--severe inflammation most HIV patients are diagnose with.
--HIV dementia many HIV patient are diagnosed with , leronlimab is crossing BBB..
--controlling to some point malignancies HIV patients are diagnosed with,
--liver problems , about 60-70% of HIV patients are diagnosed with ..
Leronlimab is a very unusual drug , and studies slowly are showing us this., and very unusual also is , that until now , in some patients close to 7 years of using , there were not one severe side effect to it..and no resistance to it in HIV.
--if CYDY is under DOJ and Sec investigation , this is VERY welcome. The sooner the better , and the more extensive the better..
--and money , yes it is , and was always not easy , but we did it until now , I don't expect problem from now on , not when we doing very well in combo in HIV , and we might be doing well in Covid , NASH , cancers and many more ,
only little more time is needed..
--and true , company is not making any money so far , but this is because of American law , I wanted to pay for my son treatment , but company told me it will be illegal for them to do it..I am sure many others will like to pay for a live saving drug , but for now law is as it is..
Lets just have the Brazilian study asap.
And good luck to leronlimab , then our patients will also be very lucky .
Finally a drug , really saving lives.
GLTA long..
All IMO.
--People dying around the world , and not one good drug approved for immune stage of covid ..
How I understand that going recently with a family member threw this terrible situation.
We need leronlimab approval asap.
--Leronlimab is also -- HIV drug ,
When refusal to file was issue , it was not because of not clinically statistical results, it was because of collateral things , not finished ROT , wrong papers file etc.
Clinical efficacy with leronlimab was as no other drug approved,
81% efficacy with 350 mg of leronlimab , compare to 45% efficacy with Maraviroc , and 43% with ibalizumab , in the same category of patients..
And so many more other benefits HIV patients should have when using leronlimab , of course studies ongoing in some , or will be initiated in others , to prove all this , but look that leronlimab will also control.
--severe inflammation most HIV patients are diagnose with.
--HIV dementia many HIV patient are diagnosed with , leronlimab is crossing BBB..
--controlling to some point malignancies HIV patients are diagnosed with,
--liver problems , about 60-70% of HIV patients are diagnosed with ..
Leronlimab is a very unusual drug , and studies slowly are showing us this., and very unusual also is , that until now , in some patients close to 7 years of using , there were not one severe side effect to it..and no resistance to it in HIV.
--if CYDY is under DOJ and Sec investigation , this is VERY welcome. The sooner the better , and the more extensive the better..
--and money , yes it is , and was always not easy , but we did it until now , I don't expect problem from now on , not when we doing very well in combo in HIV , and we might be doing well in Covid , NASH , cancers and many more ,
only little more time is needed..
--and true , company is not making any money so far , but this is because of American law , I wanted to pay for my son treatment , but company told me it will be illegal for them to do it..I am sure many others will like to pay for a live saving drug , but for now law is as it is..
Lets just have the Brazilian study asap.
And good luck to leronlimab , then our patients will also be very lucky .
Finally a drug , really saving lives.
GLTA long..
All IMO.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
